Aller au contenu principal
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
FR
FR
EN
PT
NL
NB
DE
IT
Accueil
Company Press Releases
Company press releases
Subscribe
Filtres
Filtres
Actualiser
Reset
Icon After
Date
Toggle Visibility
All
Aujourd'hui
Cette semaine
This month
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 51 - 68 of 68 results
Released
Company
Title
Industry
Topic
30 Sep 2022
08:45 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
20103010 Biotechnology
Change in Capital
26 Sep 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
20103010 Biotechnology
Other subject
31 Jul 2022
18:05 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
20103010 Biotechnology
Trends / Analyses
31 Jul 2022
18:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
20103010 Biotechnology
Trends / Analyses
23 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
20103010 Biotechnology
Trends / Analyses
22 Jun 2022
19:13 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
20103010 Biotechnology
General meeting / Board Meeting
15 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
20103010 Biotechnology
Commercial results
08 Jun 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
20103010 Biotechnology
Other subject
11 May 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
20103010 Biotechnology
General meeting / Board Meeting
28 Apr 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
20103010 Biotechnology
Commercial results, Other subject
21 Apr 2022
07:00 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
20103010 Biotechnology
Commercial results
20 Apr 2022
12:01 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
20103010 Biotechnology
Meetings / events
01 Apr 2022
08:47 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million
20103010 Biotechnology
Change in Capital
31 Mar 2022
17:45 CEST
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement
20103010 Biotechnology
Change in Capital
07 Mar 2022
07:00 CET
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
20103010 Biotechnology
Meetings / events
28 Feb 2022
01:00 CET
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease
20103010 Biotechnology
Other subject
04 Jan 2022
07:00 CET
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
20103010 Biotechnology
Meetings / events
22 Dec 2021
07:00 CET
VIVORYON THERAPEUTICS N.V.
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Pagination
«
« First
‹
‹‹
1
2
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Accueil
+ MARCHÉS
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Euronext Bruxelles
Marchés au comptant
Actions
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Obligations
ETFs
Produits structurés
Marchés dérivés
Dérivés sur Indices
Options sur Actions
Futures sur Actions
Dérivés sur Dividendes
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Euronext Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Euronext Lisbonne
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Marchés au comptant
Actions
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Obligations
ETFs
Produits structurés
Marchés dérivés
Futures sur Indices
Options sur Indices
Options sur Actions
Futures sur Actions
Dérivés sur Dividendes
Quote Vendor Codes
Communiqués sociétés
Latest
Archive
Actions
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Fonds
Directory
ESG Funds
Oslo Mutual Funds
Obligations
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Produits Structurés
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Dérivés actions & devises
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Marchandises
Cours
Vue d'ensemble
Blé de Meunerie
Colza
Maïs
European Durum Wheat Futures
Options Blé de Meunerie
Options Colza
Options Maïs
Calendriers de négociation
Livraison
Wholesale Trading
Commitments of Traders (CoT) report
Contracts specifications
Quote vendor codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Où trouver ?